ethA Resolved · high auto-curated

H37Rv Rv3854c · MTBC0 mtbc0_004087 · 489 aa · 4350114–4351583 MTBC0 (-) · RefSeq NP_218371.1

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)monooxygenase EthA
MTBC0 PGAP re-annotationFAD-containing monooxygenase EthA
Revised (this work)FAD-containing monooxygenase EthA. Pfam: Pyr_redox_2 (PF07992.21), Pyr_redox_3 (PF13738.13), NAD_binding_8 (PF13450.13), FMO-like (PF00743.26).
Functional category (TubercuList)intermediary metabolism and respiration

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 109 publications

109 TB publications mention this gene. 109 publications discuss this gene. Queried separately, 106 records carry a M. tuberculosis context and 7 a non-TB mycobacterial context (species named in the 7-record verified sample: M. smegmatis (3), M. marinum (2), M. abscessus (1), M. leprae (1)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

5 of 109: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in Mycobacterium tuberculosis. doi:10.1021/acs.jmedchem.6c01302 2026
Comparative transcriptomic profiling of pyrazinamide resistance in Mycobacterium tuberculosis. doi:10.1093/jambio/lxag064 2026
In Silico Design of gRNA for CRISPR System for Detection of Multidrug Resistant Tuberculosis Using Indian Mycobacterium tuberculosis Genomes: A Computational Study. doi:10.7759/cureus.101851 2026
Phenotypic drug resistance and genome sequencing based identified mutations linked to resistance in Mycobacterium tuberculosis isolated from extrapulmonary clinical specimens. doi:10.1038/s41598-026-40253-8 2026
Effects of mutations in multiple Ethionamide-resistance-associated genes among Mycobacterium tuberculosis clinical isolates from China. doi:10.3389/fcimb.2025.1725219 2025
112 records returned by the alias sweep (a separate sweep from the 109 above; both are shown, neither is exhaustive)

Searched as: Rv3854c, ethA, Mb3884c, ML0065, MMAR_5404, MSMEG_6440, MAB_0103 — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
Identification and characterization of ethR and ethA genes impacting the sensitivity of Mycobacterium abscessus to ethionamide. doi:10.1128/spectrum.00638-26 names it Microbiol Spectr 2026
Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in Mycobacterium tuberculosis. doi:10.1021/acs.jmedchem.6c01302 J Med Chem 2026
Comparative transcriptomic profiling of pyrazinamide resistance in Mycobacterium tuberculosis. doi:10.1093/jambio/lxag064 J Appl Microbiol 2026
In Silico Design of gRNA for CRISPR System for Detection of Multidrug Resistant Tuberculosis Using Indian Mycobacterium tuberculosis Genomes: A Computational Study. doi:10.7759/cureus.101851 Cureus 2026
Phenotypic drug resistance and genome sequencing based identified mutations linked to resistance in Mycobacterium tuberculosis isolated from extrapulmonary clinical specimens. doi:10.1038/s41598-026-40253-8 Sci Rep 2026
Effects of mutations in multiple Ethionamide-resistance-associated genes among Mycobacterium tuberculosis clinical isolates from China. doi:10.3389/fcimb.2025.1725219 Front Cell Infect Microbiol 2025
Current drug susceptibility testing in the Löwenstein-Jensen medium leads to underestimating of prothionamide resistance in multi-drug resistant Mycobacterium tuberculosis. doi:10.1186/s12866-025-04388-4 BMC Microbiol 2025
Whole-genome sequencing analysis to identify antimicrobial resistance regions and virulence factors in Mycobacterium tuberculosis isolates from the Amhara Region, Ethiopia. doi:10.1038/s41598-025-01241-6 Sci Rep 2025
Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria. doi:10.1002/mlf2.12169 mLife 2025
Phenotypic drug resistance and genetic mutations linked to resistance among extrapulmonary tuberculosis patients in Ethiopia: Insights from Whole Genome Sequencing. doi:10.21203/rs.3.rs-5302564/v1 Res Sq 2024
Universal Lineage-Independent Markers of Multidrug Resistance in Mycobacterium tuberculosis. doi:10.3390/microorganisms12071340 Microorganisms 2024
Identification of Mycobacterium tuberculosis transcriptional repressor EthR inhibitors: Shape-based search and machine learning studies. doi:10.1016/j.heliyon.2024.e26802 Heliyon 2024
Discovery of dual-active ethionamide boosters inhibiting the Mycobacterium tuberculosis ESX-1 secretion system. doi:10.1016/j.chembiol.2023.12.007 Cell Chem Biol 2024
Computational investigation of phytochemicals identified from medicinal plant extracts against tuberculosis. doi:10.1080/07391102.2023.2213341 J Biomol Struct Dyn 2024
Impact of Whole-Genome Sequencing of Mycobacterium tuberculosis on Treatment Outcomes for MDR-TB/XDR-TB: A Systematic Review. doi:10.3390/pharmaceutics15122782 Pharmaceutics 2023
Genetic Characterization Conferred Co-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Isolates from Southern Xinjiang, China. doi:10.2147/IDR.S407525 Infect Drug Resist 2023
Perchlozone Resistance in Clinical Isolates of Mycobacterium tuberculosis. doi:10.3390/antibiotics12030590 Antibiotics (Basel) 2023
Drug-Resistant Tuberculosis on the Balkan Peninsula: Determination of Drug Resistance Mechanisms with Xpert MTB/XDR and Whole-Genome Sequencing Analysis. doi:10.1128/spectrum.02761-22 Microbiol Spectr 2023
1,3-Diarylpyrazolyl-acylsulfonamides Target HadAB/BC Complex in Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.2c00392 ACS Infect Dis 2022
Increased Susceptibility of Mycobacterium tuberculosis to Ethionamide by Expressing PPs-Induced Rv0560c. doi:10.3390/antibiotics11101349 Antibiotics (Basel) 2022
Hit Compounds and Associated Targets in Intracellular Mycobacterium tuberculosis. doi:10.3390/molecules27144446 Molecules 2022
How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance. doi:10.3390/microorganisms10071436 Microorganisms 2022
First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda. doi:10.1186/s13756-022-01101-2 Antimicrob Resist Infect Control 2022
The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis. doi:10.1126/scitranslmed.aaz6280 Sci Transl Med 2022
Characterization of Fluoroquinolone-Resistant and Multidrug-Resistant Mycobacterium tuberculosis Isolates Using Whole-Genome Sequencing in Tianjin, China. doi:10.2147/IDR.S361635 Infect Drug Resist 2022
Mutation in Eth A protein of Mycobacterium tuberculosis conferred drug tolerance against enthinoamide in Mycobacterium smegmatis mc(2)155. doi:10.1016/j.compbiolchem.2022.107677 Comput Biol Chem 2022
Bioinformatic Mining and Structure-Activity Profiling of Baeyer-Villiger Monooxygenases from Mycobacterium tuberculosis. doi:10.1128/msphere.00482-21 mSphere 2022
Molecular Determinants of Ethionamide Resistance in Clinical Isolates of Mycobacterium tuberculosis. doi:10.3390/antibiotics11020133 Antibiotics (Basel) 2022
Fluorescently labelled thioacetazone for detecting the interaction with Mycobacterium dehydratases HadAB and HadBC. doi:10.1039/d1ob02080c Org Biomol Chem 2022
Abattoir survey of bovine tuberculosis in tanta, centre of the Nile delta, with in silico analysis of gene mutations and protein-protein interactions of the involved mycobacteria. doi:10.1111/tbed.14001 Transbound Emerg Dis 2022
Probing the dual inhibitory mechanisms of novel thiophenecarboxamide derivatives against Mycobacterium tuberculosis PyrG and PanK: an insight from biomolecular modeling study. doi:10.1080/07391102.2020.1844055 J Biomol Struct Dyn 2022
Whole Genome Sequencing of Drug Resistant and Drug Susceptible Mycobacterium tuberculosis Isolates From Tigray Region, Ethiopia. doi:10.3389/fmicb.2021.743198 Front Microbiol 2021
Whole genome sequencing reveals large deletions and other loss of function mutations in Mycobacterium tuberculosis drug resistance genes. doi:10.1099/mgen.0.000724 Microb Genom 2021
New ethionamide boosters and EthR2: structural and energetic analysis. doi:10.1039/d1cp02853g Phys Chem Chem Phys 2021
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis. doi:10.1021/acs.jmedchem.1c00837 J Med Chem 2021
Mycobacterial crypto-AcpM as a tool to investigate the consequence of drug binding on its key FAS II partner enzyme HadAB. doi:10.1016/j.bbagen.2021.129964 Biochim Biophys Acta Gen Subj 2021
Five-year microevolution of a multidrug-resistant Mycobacterium tuberculosis strain within a patient with inadequate compliance to treatment. doi:10.1186/s12879-021-06069-9 BMC Infect Dis 2021
Genome analyses of 174 strains of Mycobacterium tuberculosis provide insight into the evolution of drug resistance and reveal potential drug targets. doi:10.1099/mgen.0.000542 Microb Genom 2021
Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis. doi:10.1128/AAC.01445-20 names it Antimicrob Agents Chemother 2021
Genetic Variation Putatively Associated with Mycobacterium tuberculosis Resistance to Perchlozone, a New Thiosemicarbazone: Clues from Whole Genome Sequencing and Implications for Treatment of Multidrug-Resistant Tuberculosis. doi:10.3390/antibiotics9100669 Antibiotics (Basel) 2020
Prediction of treatment outcomes for multidrug-resistant tuberculosis by whole-genome sequencing. doi:10.1016/j.ijid.2020.04.043 Int J Infect Dis 2020
A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic. doi:10.1186/s12916-019-1487-2 BMC Med 2020
Focus on perchlozone, an anti-tuberculosis drug from the Russian Federation. Ceska Slov Farm 2020
Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChem. doi:10.2174/1871526519666181205163810 Infect Disord Drug Targets 2020
System OMICs analysis of Mycobacterium tuberculosis Beijing B0/W148 cluster. doi:10.1038/s41598-019-55896-z Sci Rep 2019
Improved Resistance Prediction in Mycobacterium tuberculosis by Better Handling of Insertions and Deletions, Premature Stop Codons, and Filtering of Non-informative Sites. doi:10.3389/fmicb.2019.02464 Front Microbiol 2019
Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of North West Pakistan. doi:10.1038/s41598-019-51562-6 Sci Rep 2019
Mycobacterium tuberculosis topoisomerases and EthR as the targets for new anti-TB drugs development. doi:10.4155/fmc-2018-0232 Future Med Chem 2019
Bacterial Genome-Wide Association Identifies Novel Factors That Contribute to Ethionamide and Prothionamide Susceptibility in Mycobacterium tuberculosis. doi:10.1128/mBio.00616-19 mBio 2019
New insights into the chemical behavior of S-oxide derivatives of thiocarbonyl-containing antitubercular drugs and the influence on their mechanisms of action and toxicity. doi:10.1016/j.pharma.2018.11.004 Ann Pharm Fr 2019
Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. doi:10.1016/j.cmi.2018.12.008 Clin Microbiol Infect 2019
A comprehensive analysis of the protein-ligand interactions in crystal structures of Mycobacterium tuberculosis EthR. doi:10.1016/j.bbapap.2018.12.003 Biochim Biophys Acta Proteins Proteom 2019
Integrated analysis of ethionamide resistance loci in Mycobacterium tuberculosis clinical isolates. doi:10.1016/j.tube.2018.08.010 Tuberculosis (Edinb) 2018
Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. doi:10.1093/cid/ciy609 Clin Infect Dis 2018
Role of Oxidative Stress in the Pathology and Management of Human Tuberculosis. doi:10.1155/2018/7695364 Oxid Med Cell Longev 2018
Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis. doi:10.1016/j.ejmech.2018.09.038 Eur J Med Chem 2018
Mutation EthA(W21R) confers co-resistance to prothionamide and ethionamide in both Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv. doi:10.2147/IDR.S163965 names it Infect Drug Resist 2018
A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK. doi:10.1038/s41598-018-21614-4 Sci Rep 2018
An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors. doi:10.1016/j.ejmech.2018.01.047 Eur J Med Chem 2018
Molecular Characterization of Prothionamide-Resistant Mycobacterium tuberculosis Isolates in Southern China. doi:10.3389/fmicb.2017.02358 Front Microbiol 2017
New active leads for tuberculosis booster drugs by structure-based drug discovery. doi:10.1039/c7ob00910k Org Biomol Chem 2017
Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach. doi:10.3389/fphar.2017.00681 Front Pharmacol 2017
Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of ethA as a Mechanism of Ethionamide Resistance. doi:10.1128/AAC.01461-17 names it Antimicrob Agents Chemother 2017
Update of Antitubercular Prodrugs from a Molecular Perspective: Mechanisms of Action, Bioactivation Pathways, and Associated Resistance. doi:10.1002/cmdc.201700424 ChemMedChem 2017
In Silico Prediction of Antibiotic Resistance in Mycobacterium ulcerans Agy99 through Whole Genome Sequence Analysis. doi:10.4269/ajtmh.16-0478 Am J Trop Med Hyg 2017
Cyclic di-GMP regulates Mycobacterium tuberculosis resistance to ethionamide. doi:10.1038/s41598-017-06289-7 Sci Rep 2017
Reviving a Drug for Tuberculosis? doi:10.1056/NEJMcibr1703502 N Engl J Med 2017
Fragment Screening against the EthR-DNA Interaction by Native Mass Spectrometry. doi:10.1002/anie.201702888 Angew Chem Int Ed Engl 2017
EthA/R-Independent Killing of Mycobacterium tuberculosis by Ethionamide. doi:10.3389/fmicb.2017.00710 names it Front Microbiol 2017
FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance. doi:10.1128/JCM.01662-16 J Clin Microbiol 2017
Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384. doi:10.1128/AAC.02509-16 Antimicrob Agents Chemother 2017
Assessment of a 96-Well Plate Assay of Quantitative Drug Susceptibility Testing for Mycobacterium Tuberculosis Complex in China. doi:10.1371/journal.pone.0169413 PLoS One 2017
Investigation of isoniazid and ethionamide cross-resistance by whole genome sequencing and association with poor treatment outcomes of multidrug-resistant tuberculosis patients in South Africa. doi:10.1016/j.ijmyco.2016.11.020 Int J Mycobacteriol 2016
The in vitro mechanisms of isoniazid and ethionamide resistance poorly reflect those in vivo in Mycobacterium tuberculosis. doi:10.1016/j.tube.2016.09.028 Tuberculosis (Edinb) 2016
Ethionamide biomimetic activation and an unprecedented mechanism for its conversion into active and non-active metabolites. doi:10.1039/c6ob01561a Org Biomol Chem 2016
Baeyer-Villiger Monooxygenases EthA and MymA Are Required for Activation of Replicating and Non-replicating Mycobacterium tuberculosis Inhibitors. doi:10.1016/j.chembiol.2016.05.011 names it Cell Chem Biol 2016
A review of the use of ethionamide and prothionamide in childhood tuberculosis. doi:10.1016/j.tube.2015.09.007 Tuberculosis (Edinb) 2016
Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates. doi:10.1016/j.jmii.2015.04.003 J Microbiol Immunol Infect 2016
Genome sequence comparisons of serial multi-drug-resistant Mycobacterium tuberculosis isolates over 21 years of infection in a single patient. doi:10.1099/mgen.0.000037 Microb Genom 2015
Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates. doi:10.1128/AAC.01028-15 Antimicrob Agents Chemother 2015
Characterization of a Clone of Mycobacterium tuberculosis Clinical Isolates with Mutations in KatG (A110V), EthA (Q269STOP), and the inhA Promoter (-15C→T). doi:10.1128/JCM.01537-15 names it J Clin Microbiol 2015
Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG. doi:10.1016/j.chembiol.2015.05.016 names it Chem Biol 2015
Covalent modification of the Mycobacterium tuberculosis FAS-II dehydratase by Isoxyl and Thiacetazone. doi:10.1021/id500032q ACS Infect Dis 2015
Compounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1). doi:10.1517/13543776.2015.1021333 Expert Opin Ther Pat 2015
The new tuberculosis drug Perchlozone® shows cross-resistance with thiacetazone. doi:10.1016/j.ijantimicag.2014.12.026 Int J Antimicrob Agents 2015
Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. doi:10.1128/microbiolspec.MGM2-0014-2013 Microbiol Spectr 2014
The Mycobacterium tuberculosis transcriptional repressor EthR is negatively regulated by Serine/Threonine phosphorylation. doi:10.1016/j.bbrc.2014.03.074 Biochem Biophys Res Commun 2014
An ethA-ethR-deficient Mycobacterium bovis BCG mutant displays increased adherence to mammalian cells and greater persistence in vivo, which correlate with altered mycolic acid composition. doi:10.1128/IAI.01332-13 names it Infect Immun 2014
Structural and docking studies of potent ethionamide boosters. doi:10.1107/S0108270113028126 Acta Crystallogr C 2013
High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. doi:10.1093/jac/dkt090 J Antimicrob Chemother 2013
Metabolism of the antituberculosis drug ethionamide. Curr Drug Metab 2013
Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands. doi:10.1093/nar/gkr1113 Nucleic Acids Res 2012
Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis. doi:10.1128/AAC.05649-11 Antimicrob Agents Chemother 2012
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. doi:10.1021/jm200825u J Med Chem 2012
Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives. doi:10.1016/j.bmcl.2010.12.084 Bioorg Med Chem Lett 2011
Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. doi:10.1128/AAC.01030-10 Antimicrob Agents Chemother 2011
Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs. doi:10.1111/j.1365-2672.2010.04840.x J Appl Microbiol 2010
Genotypic analysis of genes associated with isoniazid and ethionamide resistance in MDR-TB isolates from Thailand. doi:10.1111/j.1469-0691.2009.02838.x Clin Microbiol Infect 2010
Synthetic EthR inhibitors boost antituberculous activity of ethionamide. doi:10.1038/nm.1950 Nat Med 2009
Mycolic acid methyltransferase, MmaA4, is necessary for thiacetazone susceptibility in Mycobacterium tuberculosis. doi:10.1111/j.1365-2958.2009.06604.x Mol Microbiol 2009
A synthetic mammalian gene circuit reveals antituberculosis compounds. doi:10.1073/pnas.0800663105 Proc Natl Acad Sci U S A 2008
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis. doi:10.1128/AAC.00433-07 Antimicrob Agents Chemother 2007
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. doi:10.1128/AAC.01063-06 names it Antimicrob Agents Chemother 2007
Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria. doi:10.1093/jac/dkl332 J Antimicrob Chemother 2006
Insights into mechanisms of induction and ligands recognition in the transcriptional repressor EthR from Mycobacterium tuberculosis. doi:10.1016/j.tube.2005.07.005 Tuberculosis (Edinb) 2006
Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis. doi:10.1016/j.molcel.2004.09.020 Mol Cell 2004
Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance. doi:10.1016/j.jmb.2004.06.003 J Mol Biol 2004
EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. doi:10.1046/j.1365-2958.2003.03809.x Mol Microbiol 2004
ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. doi:10.1128/AAC.47.12.3799-3805.2003 names it Antimicrob Agents Chemother 2003
The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. doi:10.1074/jbc.M110751200 J Biol Chem 2002
Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. doi:10.1073/pnas.97.17.9677 Proc Natl Acad Sci U S A 2000
Activation of the pro-drug ethionamide is regulated in mycobacteria. doi:10.1074/jbc.M003744200 J Biol Chem 2000

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

Conditional expression context (iModulons)

Member of 1 independently-modulated gene set(s): Unc_2.

iModulon membership (independently-modulated gene sets from a 647-sample RNA-seq compendium): the conditional co-expression context. Co-expression is a regulatory context, NOT a molecular function. Source: iModulonDB / modulome_mtb (Yoo 2022).

CRISPRi vulnerability

Vulnerability index 0.35 (95% CI -2.14 to 3.82). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Caveat on this estimate. Bosch et al. flag this gene's vulnerability estimate as NOT certain, and here that call has a mechanical cause visible in the library itself: every guide targeting this gene is >=21 nt (str_span=0.295 on a 0-1 scale, near the genome floor), and guide repression strength saturates from 21 nt on -- so the library never sampled a partial knockdown for this gene, only the near-maximal repression plateau. The dose-response fit (and this VI) is therefore essentially unconstrained by data, not merely uncertain -- a limitation of the CRISPRi library design for the non-essential class (Bosch et al. 2021), not a defect in this specific measurement. n_guides=12 is descriptive only and does not predict this. Do not cite this VI as a standalone vulnerability claim.

Legacy record & comparison (Mycobrowser)

Mycobrowser functionActivates the pro-drug ethionamide (ETH); induced ETH sensitivity when overexpressed in Mycobacterium tuberculosis.
Mycobrowser EC 1.-.-.- · superseded EC numbering; the atlas uses the current class (1.14.13.-)

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb3884c · 100.0% identity
M. leprae ML0065 · 80.1% identity
M. marinum MMAR_5404 · 85.5% identity
M. smegmatis MSMEG_6440 · 65.4% identity
M. orygis RJtmp_003970 · 99.8% identity
M. abscessus MAB_0103 · 61.0% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt P9WNF9 SwissProt · reviewed · Evidence at protein level
UniProt nameFAD-containing monooxygenase EthA
EC (curated) EC 1.14.13.-
Curated functionMonooxygenase able to convert a wide range of ketones to the corresponding esters or lactones via a Baeyer-Villiger oxidation reaction. Can act on long-chain aliphatic ketones (2-hexanone to 2-dodecanone) and on aromatic ketones (phenylacetone and benzylacetone). Is also able to catalyze enantioselective sulfoxidation of methyl-p-tolylsulfide. In vivo, likely functions as a BVMO, but the exact nature of the physiological substrate(s) remains to be established..; FUNCTION: Is responsible for the activation of several thiocarbamide-containing pro-drugs into cytotoxic species. Thus, catalyzes the.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category P Inorganic ion transport and metabolism
Preferred nameethA
eggNOG descriptionmonooxygenase EthA
Orthologous groupCOG2072
KEGG orthology K10215
KEGG pathways map00627, map01120
Gene Ontology (42) GO:0000166, GO:0003674, GO:0003824, GO:0004497, GO:0004499, GO:0005488, GO:0005575, GO:0005618, GO:0005622, GO:0005623, GO:0005737, GO:0005829 +30 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS 0.814 · relaxed/neutral
Polymorphic sites (≥ 0.1% of strains) 5 synonymous, 13 missense, 0 nonsense, 7 frameshift
Disruption 7 distinct premature-stop/frameshift site(s); most common in 0.59% of strains (841) · convergent
Which clade carries which site (attribution) aucun site fixé dans un clade; union over all sites: 2 355 strains (the count above is a maximum over sites, not a union).
  • NC_000962.3:4327362:CT:C · frameshift · 841 strains — not fixed in any clade
  • NC_000962.3:4326704:GC:G · frameshift · 374 strains — not fixed in any clade
  • NC_000962.3:4326832:GAC:G · frameshift · 307 strains — not fixed in any clade
  • NC_000962.3:4326248:TGTAATTCAAC:T · frameshift · 289 strains — not fixed in any clade
  • NC_000962.3:4326086:GT:G · frameshift · 237 strains — not fixed in any clade
  • NC_000962.3:4326769:TA:T · frameshift · 162 strains — not fixed in any clade
  • NC_000962.3:4327131:GT:G · frameshift · 145 strains — not fixed in any clade
Which clade carries which disrupting site — the question the count above never asked. `disrupt_strains` is a MAXIMUM over sites, not a union: two sites carried by two disjoint clades do not add up there. `disrupt_mode` is derived from the NUMBER of sites alone (convergent at 4 or more), so it says nothing about who carries them. Read this field instead for any evolutionary claim, and mind the distinction it enforces: several clades at the SAME site is shared ancestry, not convergence — convergence requires DIFFERENT sites in DIFFERENT clades. SECOND CORRECTION (P44.8, same day): a clade name listed here is the ROOT of the fine clade that fixes the site, not the whole lineage. Across the 789 fixed sites of this atlas, the fixing sub-clades cover a median of 9.2% of the lineage named, and under 10% for half of them — so read the sub-clade sizes given here, never the lineage name alone.

Read the disruption percentage against its ceiling, not against 100%. The strain collection is deeply imbalanced by clade, so a loss fixed in an entire lineage still shows a small overall fraction: a gene disrupted in every L6 strain caps at 0.96% of the collection, in every M. caprae strain at 0.20%, in every M. microti strain at 0.02%. Of the 705 clades in this collection, 689 have a ceiling below 1%. A figure of "0.15% of strains" is therefore uninterpretable on its own — it can be noise or a complete, lineage-defining loss. Use the clade attribution row above, which gives the sub-clade sizes, and never read the percentage alone.

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Corynebacteriales

M. canettii dN/dS (deep-divergence selection) 0.313 (low power) · 2 consensus substitution(s)
low power (2 canettii-consensus substitution(s)); present in M. canettii but dN/dS not reliable
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 53/53 (100%) · mean identity 75.4% · 4/4 closest MTBAP relatives
conserved across the genus (present in 53/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 5/13 non-Mycobacterium reference genomes (down to Corynebacteriales) · mean identity 55.1%
detected across the order Corynebacteriales (Corynebacterium/Nocardia/Rhodococcus/…) but not in more distant Actinomycetia — a Corynebacteriales-level gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis)

DeJesus 2017 callNE · non-essential
What the call meansnon-essential
TA sites (Himar1) 31 in the ORF — 0 in the essential state, 0 growth-defect, 31 non-essential, 0 growth-advantage. Saturation 1.000, mean read count 158.064516129. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 31 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Drug resistance (WHO catalogue) ethionamide

ethionamide1276 catalogued resistance-associated variant(s)

This gene carries mutations classed Associated with resistance (WHO grade 1–2) in the consolidated catalogue (WHO 2nd ed. 2023 + tb-profiler). Only the R-associated tier is shown; "uncertain" and empirical-only signals are excluded. Test a specific strain or variant with the resistance tester. Research context, not a clinical diagnostic.

Proteomics (mass spectrometry) detected

MS detectiondetected in 12 of 16 independent MS datasets
Integrated abundance81.1 ppm · rank 1449/3519 (58.9th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox) no export signal, no TM helix

Predictionno signal peptide, no TM helix (DeepTMHMM class GLOB)
DeepTMHMM classGLOB

A verified absence of signals, which is not a compartment. No Sec/Tat signal peptide, no transmembrane helix and no lipobox were found on this sequence. The predictor reports topology and export signals; it does not measure where the protein ends up, so this page draws no cytoplasmic conclusion from it. In M. tuberculosis that reservation is not theoretical: the 12 Esx paralogues of this atlas — EsxA/ESAT-6 and EsxB/CFP-10 among them, the best-established secreted proteins of the species — carry this very call, because substrates of the type VII (ESX) secretion system leave no recognisable signal. « Secreted » and « no signal peptide » are true together here.

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length489 aa
Molecular weight55.3 kDa
Theoretical pI8.38
GRAVY-0.3 (hydrophilic)
Aliphatic index82.0
Aromaticity0.104
Instability index41.8 (unstable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
Pyr_redox_2PF07992.21 3.1e-066–212 Pyridine nucleotide-disulphide oxidoreductase
Pyr_redox_3PF13738.13 1.2e-078–211 Pyridine nucleotide-disulphide oxidoreductase
NAD_binding_8PF13450.13 3.1e-089–57 NAD(P)-binding Rossmann-like domain
FMO-likePF00743.26 1.3e-1180–346 Flavin-binding monooxygenase-like

3D structure (interactive — Mol*/pdbe-molstar)

No experimental structure is deposited for this gene: showing the AlphaFold DB predicted model (mean pLDDT 94.8, very high), coloured by per-residue confidence (dark blue = very high, orange/red = low — treat low-confidence regions as unreliable, especially termini and loops). Drag to rotate, scroll to zoom.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 94.8

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
4ap3-assembly1_A 1.00 0.75 0.75 0.71 21% 98% / 100% 2.2e-30 sig 4ap3-assembly1_A Oxidized steroid monooxygenase bound to NADP
4ap1-assembly1_A 1.00 0.76 0.76 0.72 22% 98% / 100% 5.0e-30 sig 4ap1-assembly1_A Oxidized steroid monooxygenase bound to NADP
4d03-assembly1_A 1.00 0.73 0.71 0.66 22% 86% / 87% 6.6e-30 sig 4d03-assembly1_A Structure of the Cys65Asp mutant of phenylacetone monooxygenase: oxidised state
2ylr-assembly1_A 1.00 0.75 0.75 0.69 20% 98% / 99% 5.6e-30 sig 2ylr-assembly1_A SNAPSHOTS OF ENZYMATIC BAEYER-VILLIGER CATALYSIS: OXYGEN ACTIVATION AND INTERMEDIATE STABILIZATION: COMPLEX WITH NADP
3uoz-assembly1_A 1.00 0.74 0.74 0.68 20% 98% / 100% 1.1e-29 sig 3uoz-assembly1_A Crystal Structure of OTEMO complex with FAD and NADP (form 2)

Foldseek search of the AlphaFold DB model (mean pLDDT 94.8, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Genomic context (neighbours & predicted operon)

Upstream (5' on genome)rraA (+ strand, 35 bp gap)
Downstream (3' on genome)ethR (+ strand, 75 bp gap)

Neighbours from the H37Rv annotation (- strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) no multi-gene operon predicted (singleton)
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT3969) expressed, no multi-gene operon (exponential phase, coverage 401.56)
expressed, no multi-gene operon (stationary phase, coverage 131.55) — agrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Transcriptional regulation (signed TRN: ChIP-seq + TFOE)

Regulated by (3 TF) Rv0324 (activates) · Rv2250c (represses) · ethR (represses)

Regulatory edges from the ISB signed transcriptional regulatory network (TF ChIP-seq binding, Minch 2015 + TF-overexpression response, Rustad 2014). An edge is regulatory evidence (binding and/or expression change), not necessarily direct. For a "hypothetical", membership in a known regulon (e.g. DosR dormancy, PhoP virulence) is a physiological-context lead, not a function.

Condition: Condition-blind by construction. These edges come from transcription-factor OVEREXPRESSION in a single laboratory condition, so a listed regulator is not a claim that it governs this gene in every circumstance. Measured counter-examples exist within this atlas (see Rv2516c, where the DosR regulon collapses under moxifloxacin while the gene itself rises). Read a regulator as 'capable of shifting this gene', and look for the condition before building a hypothesis on it.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: ethR (HTH-type transcriptional repressor EthR), high confidence (score 709, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence).

Showing the 15 strongest of this gene's 27 partners at medium confidence (2 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. None of the 27 partners rests on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv3083 mymA curated paralog FAD-containing monooxygenase MymA 906 905 database:900
Rv3855 ethR HTH-type transcriptional repressor EthR 935 709 ctx neighborhood:604 textmining:786
Rv0943c dark monooxygenase 558 558 ctx cooccurence:558
Rv1308 atpA exp (transferred) ATP synthase subunit alpha 435 436 experimental:427
Rv1507c hypothetical protein 412 413
Rv1309 atpG ATP synthase subunit gamma 409 409
Rv3456c rplQ 50S ribosomal protein L17 407 408
Rv1310 atpD ATP synthase subunit beta 401 402
Rv3461c rpmJ 50S ribosomal protein L36 401 401
Rv3846 sodA superoxide dismutase 405 396
Rv0363c fba fructose-bisphosphate aldolase 414 391
Rv2373c dnaJ2 chaperone protein DnaJ 406 384
Rv0352 dnaJ1 chaperone protein DnaJ 401 379
Rv0701 rplC 50S ribosomal protein L3 518 351
Rv0682 rpsL 30S ribosomal protein S12 420 351

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: monooxygenase EthA
  • MTBC0 PGAP product: FAD-containing monooxygenase EthA
  • Pfam (hmmscan --cut_ga): Pyr_redox_2 PF07992.21 (E=3e-06), Pyr_redox_3 PF13738.13 (E=1e-07), NAD_binding_8 PF13450.13 (E=3e-08), FMO-like PF00743.26 (E=1e-11)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_218371.1)
  • Domains: Pfam-A via hmmscan --cut_ga — Pyr_redox_2 (PF07992.21), Pyr_redox_3 (PF13738.13), NAD_binding_8 (PF13450.13), FMO-like (PF00743.26)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG2072
  • Curated reference: UniProt P9WNF9 (SwissProt, reviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 94.8)
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 27 functional partner(s); context anchor ethR
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Transcriptional regulation: ISB signed TRN — TF ChIP-seq (Minch et al. 2015, doi:10.1038/ncomms6829) + TF overexpression (Rustad et al. 2014, doi:10.1186/gb-2014-15-11-502)
  • Drug resistance: consolidated catalogue, WHO 2nd ed. 2023 (9789240082410) + tb-profiler; only the resistance-associated tier (grade 1–2) is surfaced
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_004087|Rv3854c|ethA
MTEHLDVVIVGAGISGVSAAWHLQDRCPTKSYAILEKRESMGGTWDLFRYPGIRSDSDMYTLGFRFRPWTGRQAIADGKPILEYVKSTAAMYGIDRHIRFHHKVISADWSTAENRWTVHIQSHGTLSALTCEFLFLCSGYYNYDEGYSPRFAGSEDFVGPIIHPQHWPEDLDYDAKNIVVIGSGATAVTLVPALADSGAKHVTMLQRSPTYIVSQPDRDGIAEKLNRWLPETMAYTAVRWKNVLRQAAVYSACQKWPRRMRKMFLSLIQRQLPEGYDVRKHFGPHYNPWDQRLCLVPNGDLFRAIRHGKVEVVTDTIERFTATGIRLNSGRELPADIIITATGLNLQLFGGATATIDGQQVDITTTMAYKGMMLSGIPNMAYTVGYTNASWTLKADLVSEFVCRLLNYMDDNGFDTVVVERPGSDVEERPFMEFTPGYVLRSLDELPKQGSRTPWRLNQNYLRDIRLIRRGKIDDEGLRFAKRPAPVGV